Ultrasound drug delivery with chemotherapy for HER2-positive breast cancer
Part of Cancer clinical trials.
This study tests a new technique that uses focused ultrasound to deliver cancer drugs directly to breast tumors, combined with standard chemotherapy. The goal is to improve treatment effectiveness for HER2-positive breast cancer before surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 18–70 years old
- You have been diagnosed with HER2-positive breast cancer (confirmed by biopsy) that needs chemotherapy before surgery
- Your cancer is stage T2N0-2M0 (a specific size and lymph node involvement, with no spread to other organs)
- Your blood cell counts and liver/kidney function are adequate to handle chemotherapy safely
- Your heart is healthy enough for treatment (ejection fraction ≥50%)
- You have not previously received chemotherapy or radiation therapy for any cancer
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies how well a HER2-focused treatment plan works before surgery (“neoadjuvant” therapy) for operable HER2-positive breast cancer. It also uses tumor tissue tests to find markers that may predict who benefits most.
This trial tests a combination of targeted drugs (Initumab and Pyrrotinib) plus chemotherapy before surgery for HER2-positive breast cancer. It compares different treatment lengths to see which is more effective and safe.
This trial tests a new targeted drug (BL-M07D1) with or without another drug called pertuzumab, compared to a standard chemotherapy plus two targeted drugs, before surgery for HER2-positive breast cancer. The goal is to see if the new combination works better at shrinking tumors before surgery.
This Phase 2 study tests a personalized immune-therapy vaccine made from your immune cells, given with weekly paclitaxel and HER2-targeted antibodies (trastuzumab and pertuzumab). It aims to improve treatment outcomes for people with HER2-positive breast cancer before standard local treatment (like surgery and radiation).
This trial tests a combination of two drugs, trastuzumab deruxtecan (SHR-A1811) and pertuzumab, given before surgery to shrink HER2-positive breast cancer. It is for women with stage II or III breast cancer who have not yet had treatment and are in good overall health.
This trial tests whether adding focused ultrasound (HIFU) and an immunotherapy drug (PD-1 inhibitor) before standard chemotherapy can improve outcomes for women with stage II or III triple-negative breast cancer (TNBC). It aims to find a more effective way to shrink tumors before surgery.
Hear when a new HER2-positive Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.